Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric AI-driven biotechnology company and pioneer in precision medicine, has announced a multi-year collaboration and license agreement with Genentech, a member of the Roche Group. Under the partnership, Caris Discovery, the company’s therapeutic research arm, will work to identify and validate novel oncology targets in solid tumors, with a focus on cancers that have high unmet clinical need. As part of the agreement, Caris is eligible to receive upfront and near-term payments totaling $25 million. The company may also earn up to $1.1 billion in potential milestone payments tied to research, development, commercialization, and net sales of therapies resulting from the collaboration, along with potential tiered royalties on future product sales. Milan Radovich, PhD, Senior Vice President and Chief Scientific Officer at Caris, emphasized the mission behind the partnership. “At Caris, we are committed to making precision medicine a reality for all patients. This innovative collaboration with Genentech is specifically designed to identify and validate novel targets in solid tumors. By combining Caris’ unparalleled multimodal data and tissue-based discovery engine with Genentech’s deep expertise in therapeutics development, we hope to enable the development of first-in-class medicines for cancer patients.” Boris L. Zaïtra, Head of Roche Corporate Business Development, highlighted Genentech’s long-standing commitment to advancing oncology. “Roche and Genentech are driven by a profound vision – a future where cancer can be cured. We have successfully led many fundamental scientific advances in oncology. As we continue to bring forth transformative medicines, collaborations with partners such as Caris allow us to pursue future innovation for patients with unmet needs.” Caris leverages its extensive repository of nearly 500,000 solid tumor samples, each accompanied by comprehensive molecular and clinical data, to power its target discovery platform. The company employs an integrated bioinformatics and wet-lab workflow that combines tissue-based analysis with data-centric approaches to prioritize and validate potential therapeutic targets. Headquartered in Irving, Texas, Caris operates offices in Phoenix, New York, Cambridge, Massachusetts, Tokyo, Japan, and Basel, Switzerland. The company and its distributor partners provide services across the U.S. and international markets. The press release includes forward-looking statements regarding the collaboration’s strategy, potential milestones, and financial outcomes. These statements are based on current expectations but involve risks and uncertainties, including the ability to successfully execute the research plan, Genentech’s decisions on target selection and development, technical challenges in target validation, regulatory hurdles, and the risk that discoveries may not progress to market. Actual results may differ materially due to factors such as competitive dynamics, market acceptance, data security, regulatory compliance, and the company’s ability to attract and retain key personnel. Caris undertakes no obligation to update these statements except as required by law.